Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATIFY phase III trial of ceralasertib plus durvalumab versus docetaxel in previously treated advanced non-small cell lung cancer
jRCT2031220611Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ceralasertib plus durvalumab with Docetaxel monotherapy (2 arms). Primary endpoint: Overall Survival. Started Feb 2023; status: active, not recruiting.
02
Drugs
ceralasertibdurvalumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220611.